Skip to main content
. 2019 Nov 6;5(2):260–268. doi: 10.1016/j.adro.2019.10.006

Figure 2.

Figure 2

Example images, dose distributions, and cumulative dose-volume histogram (DVH) curves for 2 patients with prescription doses of 27 Gy in 3 fractions (a-e) and 35 Gy in 5 fractions (f-j), respectively. Subfigures include (a, f) prostate-specific membrane antigen/positron emission tomography (PSMA-PET) coregistered with the simulation computed tomography, (b, g) clinical SABR, (c, h) research SABR, and (d, i) biology-guided radiation therapy (BgRT) dose distributions and (e, j) cumulative DVH curves. (e, j) Solid, dashed, and dotted lines correspond to the CSABR, RSABR, and BgRT plans, respectively. Note that the BgRT dose distribution in (i) does not exactly match the PSMA-PET uptake in (f), resulting from the DVH-based plan optimization, which does not directly optimize dose based on radiotracer uptake. Abbreviation: PTV = planning target volume.